We are live on ! Find out more
UOC

UBS O'Connor Portfolio holdings

AUM $3.38B
1-Year Est. Return 63.08%
This Fund
S&P 500
This Quarter Est. Return
+16.95%
1 Year Est. Return
+63.08%
3 Year Est. Return
+180.99%
5 Year Est. Return
+483.22%
10 Year Est. Return
+2,128.62%
AUM
$1.52B
AUM Growth
-$7.28B
Cap. Flow
-$6.76B
Cap. Flow %
-444.29%
Top 10 Hldgs %
100%
Holding
929
New
Increased
6
Reduced
3
Closed
920

Sector Composition

Rank Sector Weight
1 Technology 45.54%
2 Healthcare 36.97%
3 Financials 14.43%
4 Communication Services 3.06%
5 Energy 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
OSI
476
DELISTED
Osiris Acquisition Corp.
OSI
-237,693
Closed -$2.33M
SCRM
477
DELISTED
Screaming Eagle Acquisition Corp. Class A Ordinary Shares
SCRM
-2,573,487
Closed -$24.9M
PMGMW
478
DELISTED
Priveterra Acquisition Corp. II Warrant to purchase Class A common stock
PMGMW
-80,120
Closed -$9K
PMGM
479
DELISTED
Priveterra Acquisition Corp. II Class A Common Stock
PMGM
-233,953
Closed -$2.33M
CONX
480
DELISTED
CONX Corp. Class A Common Stock
CONX
-487,994
Closed -$4.88M
CONXW
481
DELISTED
CONX Corp. Warrant
CONXW
-475,238
Closed -$36K
LGVC
482
DELISTED
LAMF Global Ventures Corp. I Class A Ordinary Shares
LGVC
-381,797
Closed -$3.85M
DSAQ
483
DELISTED
Direct Selling Acquisition Corp.
DSAQ
-240,492
Closed -$2.44M
AEON.WS
484
DELISTED
AEON Biopharma Inc
AEON.WS
-112,473
Closed -$8K
USCT
485
DELISTED
Roth CH Acquisition Co. Class A Ordinary Shares
USCT
-381,797
Closed -$3.87M
RMGCW
486
DELISTED
RMG Acquisition Corp. III Warrant
RMGCW
-190,094
Closed -$17K
RMGC
487
DELISTED
RMG Acquisition Corp. III Class A Ordinary Shares
RMGC
-711,918
Closed -$7.08M
EIGR
488
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
-7,401
Closed -$1.67M
AVHI
489
DELISTED
Achari Ventures Holdings Corp I
AVHI
-238,623
Closed -$2.4M
MVLA
490
DELISTED
Movella Holdings Inc. Common Stock
MVLA
-239,519
Closed -$2.38M
CPE
491
PUT
DELISTED
Callon Petroleum Company
CPE
-78,700
Closed -$232K
TWOA
492
DELISTED
two
TWOA
-238,623
Closed -$2.36M
PEPL
493
DELISTED
PepperLime Health Acquisition Corporation Class A Ordinary Share
PEPL
-238,623
Closed -$2.38M
PEPLW
494
DELISTED
PepperLime Health Acquisition Corporation Warrrant
PEPLW
-73,355
Closed -$5K
PORT
495
DELISTED
Southport Acquisition Corporation
PORT
-374,325
Closed -$3.76M
HCMA
496
DELISTED
HCM Acquisition Corp Class A Ordinary Shares
HCMA
-187,163
Closed -$1.89M
ROSS
497
DELISTED
Ross Acquisition Corp II
ROSS
-476,006
Closed -$4.72M
ALTUW
498
DELISTED
Altitude Acquisition Corp Warrant
ALTUW
-238,623
Closed -$15K
TGVC
499
DELISTED
TG Venture Acquisition Corp. Class A Common Stock
TGVC
-233,953
Closed -$2.34M
SAGA
500
DELISTED
Sagaliam Acquisition Corp. Class A Common Stock
SAGA
-233,953
Closed -$2.34M

Similar funds

UBS O'Connor's Q4 2022 Portfolio in Review

As of Q4 2022, UBS O'Connor held 929 positions worth $1.52B, down 83% from $8.8B the previous quarter. Its ten largest holdings account for 100% of the portfolio.

UBS O'Connor withdrew a net $6.76B in Q4 2022, closing 920 positions and reducing 3 holdings. Its most notable exit was Biohaven Pharmaceutical Holding Company Ltd., an estimated $572M position sold in full.

By sector, the portfolio is most concentrated in Technology at 46% of assets, up from 28% a quarter earlier, followed by Healthcare and Financials.

Against the trend, UBS O'Connor added an estimated $184M to Horizon Therapeutics Public Limited Company Ordinary Shares.

  • UBS O'Connor added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2022, an estimated $184M increase.
  • UBS O'Connor's biggest Q4 2022 reduction was Activision Blizzard, cutting an estimated $45.3M.
  • UBS O'Connor fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q4 2022, selling an estimated $572M.
  • UBS O'Connor's ten largest holdings make up 100% of its $1.52B portfolio in Q4 2022.
  • UBS O'Connor opened 0 new positions and closed 920 in Q4 2022.
  • UBS O'Connor's portfolio value fell 83% quarter-over-quarter to $1.52B.

Based on UBS O'Connor's 13F filing for Q4 2022, filed 14 Feb 2023.